Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC Pembrolizumab Plus Axitinib a New Standard in Metastatic RCC

First-line treatment with the anti-PD-1 immunotherapy pembrolizumab plus the VEGF-targeted tyrosine-kinase inhibitor axitinib extended overall survival and progression-free survival in patients with clear-cell metastatic renal cell carcinoma (mRCC), compared with the current standard of care, sunitinib, in the phase 3 KEYNOTE-426 trial.Reuters Health Information (Source: Medscape Allergy Headlines)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2E3FBEn